Advertisement

Clinical Drug Investigation

, Volume 39, Issue 2, pp 215–215 | Cite as

Correction to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study

  • Daniel R MoralesEmail author
  • Jim Slattery
  • Alexandra Pacurariu
  • Luis Pinheiro
  • Patricia McGettigan
  • Xavier Kurz
Open Access
Correction
  • 48 Downloads

1 Correction to: Clinical Drug Investigation  https://doi.org/10.1007/s40261-018-0729-y

The article Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study, written by Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X, was originally published Online First without open access. After publication the authors requested that the article be Open Choice to make the article an open access publication. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article has been corrected.​

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Division of Population Health and Genomics, School of MedicineUniversity of DundeeDundeeUK
  2. 2.Pharmacovigilance and Epidemiology DepartmentEuropean Medicines AgencyLondonUK
  3. 3.William Harvey Research InstituteQueen Mary University of LondonLondonUK

Personalised recommendations